• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Lung Cancer Drug Pipeline Update 2014 Product Image

Lung Cancer Drug Pipeline Update 2014

  • ID: 1197058
  • July 2014
  • Region: Global
  • Bioseeker

Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) comprises over 95% of all lung cancers. High unmet needs still persist for this tumor type and despite two decades of extensive R&D and chemotherapy use, the median overall survival of NSCLC patient’s remains below 12 months. Mesothelioma is rarer, although incidence is expected to increase in the coming years in Europe and Japan given the heavy use of asbestos in the 1970s and long latency period of the disease.
There are today 368 companies plus partners developing 517 lung cancer drugs in 609 developmental projects in cancer. In addition, there are 11 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 224 drugs. Lung Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 331 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 319 out of the 322 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational READ MORE >

Delivery Format: Desktop App plus Online Access to Updates (One Year)

Note: Product cover images may vary from those shown


Our Clients

Our clients' logos